Bio-Thera Solutions has begun dosing in Phase I trials for its BAT2206 proposed biosimilar ustekinumab. The Chinese firm received a local go-ahead for its Phase I trial for the rival to Janssen’s Stelara towards the end of 2019. (Also see "Bio-Thera Gets Chinese Nod To Proceed On Ustekinumab" - Generics Bulletin, 12 December, 2019.)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?